title: Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients.
abstract: OBJECTIVE
  We dynamically observed the expression of CD152 and PD-1 on T-cell surfaces in peripheral blood of liver allorecipients to explore the regulatory effect of FK506 on negative costimulatory molecules.
  
  
  METHODS
  We evaluated 20 liver allorecipients, 19 end-stage liver disease patients, and 20 healthy volunteers for FK506 concentrations measured by an enzyme-multiplied immunoassay technique and flow cytometry to determine T-cell subsets as well as CD152 and PD-1 expression.
  
  
  RESULTS
  After liver transplantation, the frequency of CD4+ T cells gradually decreased to significantly lower level than those in the disease controls (P < .05). CD8+ T cells in each treatment group were obviously higher than those in the disease controls (P < .05). The expression of CD152 on CD4+ and CD8+ T cells was greater than those in healthy controls (P < .05); and at 2 and 4 weeks, higher than those in disease controls (P < .05). The expression of PD-1 on CD4+ T cells from the 2 weeks after treatment was significantly greater than that in healthy controls (P < .05), and that on CD8+ T cells increased obviously from the 4 weeks compared with disease controls (P < .05).
  
  
  CONCLUSIONS
  FK506 up-regulated the expression of CD152 and PD-1 on the T-cell surface inhibiting proliferation and activation of effector T cells, favoring the survival of allorecipients.
authors.affiliation: Division of Clinical Immunological Laboratory, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Bai
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: H
authors.initials: H
authors.lastname: Wei
authors.forename: B
authors.initials: B
authors.lastname: Cai
authors.forename: L
authors.initials: L
authors.lastname: Yan
authors.forename: H
authors.initials: H
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000187:drug effects*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D023201:CD40 Ligand / Q000187:drug effects*; D016827:CD8 Antigens / Q000032:analysis; D006801:Humans; D017093:Liver Failure / Q000276:immunology; D016031:Liver Transplantation / Q000276:immunology*; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor; D012016:Reference Values; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D015703:Antigens, CD; D051017:Apoptosis Regulatory Proteins; D016827:CD8 Antigens; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D023201:CD40 Ligand; D016559:Tacrolimus